Skip to main content
Figure 3 | BMC Urology

Figure 3

From: Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial

Figure 3

Adjusted mean change from baseline to final visit (SE) by treatment group in mean number of micturitions/24 h (FAS) for subgroups of patients who received prior antimuscarinic OAB medication; who discontinued it because of either insufficient efficacy or poor tolerability † ; and for those who were antimuscarinic treatment-naïve.

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us